Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 1;128(2):556-563.
doi: 10.1172/JCI97509. Epub 2018 Feb 1.

Blood will out: vascular contributions to Alzheimer's disease

Review

Blood will out: vascular contributions to Alzheimer's disease

Sidney Strickland. J Clin Invest. .

Abstract

The fundamental pathology in Alzheimer's disease (AD) is neuronal dysfunction leading to cognitive impairment. The amyloid-β peptide (Aβ), derived from amyloid precursor protein, is one driver of AD, but how it leads to neuronal dysfunction is not established. In this Review, I discuss the complexity of AD and possible cause-and-effect relationships between Aβ and the vascular and hemostatic systems. AD can be considered a multifactorial syndrome with various contributing pathological mechanisms. Therefore, as is routinely done with cancer, it will be important to classify patients with respect to their disease signature so that specific pathologies, including vascular pathways, can be therapeutically targeted.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The author has declared that no conflict of interest exists.

Figures

Figure 1
Figure 1. Multiple pathogenic pathways contribute to and provide therapeutic targets for AD.
While neuronal dysfunction is the defining pathology underlying cognitive decline in AD, this disease is likely the product of multiple pathogenic mechanisms and might benefit from combination therapy (–130). Increasing evidence implicates vascular dysfunction in AD pathogenesis. Aβ plaques and tau tangles drive neuronal dysfunction and neuroinflammation through mechanisms that are not fully established. Aβ is also implicated in vascular pathology, having been shown to interact with fibrin(ogen) and the contact system. The prevalence of vascular dysfunction in patients exhibiting cognitive decline suggests that combining existing treatment strategies targeting neuronal dysfunction (e.g., cholinesterase inhibitors) and vascular dysfunction (e.g., antiinflammatory, antihypertensive, or anticoagulant medications) may advance AD treatment efficacy.
Figure 2
Figure 2. Possible influence of Aβ on fibrin deposition and AD pathology.
The interaction of Aβ with fibrinogen leads to increased formation of structurally abnormal fibrin clots that are resistant to degradation. This persistent fibrin and resulting predisposition towards blood vessel occlusion and inflammation could contribute to the neurodegeneration observed in AD. Images reproduced with permission from Cortes-Canteli et al. (53).
Figure 3
Figure 3. The contact activation system.
Aβ-mediated dysregulation or overactivation of the contact system could contribute to the coagulopathy and inflammation observed in AD. Aβ can trigger activation of factor XII (FXII) into FXIIa. FXIIa’s activation of FXI initiates the intrinsic coagulation system and fibrin formation, whereas its activation of plasma prekallikrein leads to inflammation. PPK, plasma prekallikrein; PK, plasma kallikrein; HK, high molecular weight kininogen; HKc, cleaved HK. a = activated form.

Similar articles

Cited by

References

    1. Jack CR, Jr, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–216. doi: 10.1016/S1474-4422(12)70291-0. - DOI - PMC - PubMed
    1. Nixon RA, Yang DS. Autophagy failure in Alzheimer’s disease — locating the primary defect. Neurobiol Dis. 2011;43(1):38–45. doi: 10.1016/j.nbd.2011.01.021. - DOI - PMC - PubMed
    1. Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease. Mol Neurodegener. 2014;9:48. - PMC - PubMed
    1. Mamelak M. Energy and the Alzheimer brain. Neurosci Biobehav Rev. 2017;75:297–313. doi: 10.1016/j.neubiorev.2017.02.001. - DOI - PubMed
    1. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2(1):a006346. - PMC - PubMed

Publication types